Castration-Resistant Prostate Cancer: What to Know - WebMD
2024年6月19日 · Prognosis for CRPC. In clinical trials, the newest drugs for nmCRPC can delay the spread of prostate cancer for an average of up to nearly 3 1/2 years.People who took these drugs lived up to an ...
Metastatic Castration-Resistant Prostate Cancer: Insights on …
Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: outcomes from the randomized controlled phase 3 AFFIRM trial. Cancer. 2017;123:253–262. doi: 10.1002/cncr.30336 [PMC free article] [Google Scholar] 36. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate ...
Overview of the treatment of castration-resistant prostate cancer (CRPC ...
Overview of the treatment of castration-resistant prostate cancer (CRPC ...
Definition of Castrate Resistant Prostate Cancer: New Insights
Current definition of Castrate Resistant Prostate Cancer. We aim to review the new insights from more efficient imaging modalities than those currently proposed by RECIST 1.1 for the assessment of PCa clinical progression, as well as the new insights regarding the best methods to assess the castration environment, in order to improve the current definition of CRPC and the …
What is castration-resistant prostate cancer? - Medical News Today
2023年7月14日 · Castration-resistant prostate cancer (CRPC) advances even after a person receives treatment to dramatically lower testosterone levels. Further treatment may aim to prevent cancer from spreading to ...
Asymptomatic non-metastatic CRPC One of the first clinical presentations of CRPC occurs in a patient with a rising PSA despite medical or surgical castration. This is typically defined as a patient with a rising PSA and no radio-logic evidence …
Castration-Resistant Prostate Cancer: Treatment, Outlook, and …
2020年8月24日 · What Is Castration-Resistant Prostate Cancer and Is It Treatable? Medically reviewed by Yamini Ranchod, Ph.D., M.S. — Written by Daniel Pendick — Updated on August 24, 2020 Hormones and cancer
Castration-Resistant Prostate Cancer: From Uncovered …
Castration-resistant prostate cancer (CRPC) remains a significant medical challenge, even with recent advancements in diagnosis and treatment. To improve patient outcomes, it is important to understand the underlying mechanisms of resistance to treatments and develop new therapeutic approaches. This review provides a brief summary of the ...
Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer. With CRPC, the cancer no longer completely responds to treatments that lower testosterone. It shows signs of growth, like a rising PSA (prostate-specific antigen), even with low levels of testosterone. With Metastatic CRPC (mCRPC), the cancer stops
What Is Metastatic Castration-Resistant Prostate Cancer (mCRPC)?
2024年5月15日 · Types of Castration-Resistant Prostate Cancer . Castration-resistant prostate cancers are a class of cancer that do not respond to first-line treatments, which include surgery and/or a standard hormone treatment called androgen-deprivation therapy (ADT). While treatments for mCRPC can be highly effective, especially if the disease is caught ...